+353-1-416-8900REST OF WORLD
+44-20-3973-8888REST OF WORLD
1-917-300-0470EAST COAST U.S
1-800-526-8630U.S. (TOLL FREE)
GLP-1 Receptor Agonist Market - Global Forecast 2025-2030- Product Image
GLP-1 Receptor Agonist Market - Global Forecast 2025-2030- Product Image
Sale

GLP-1 Receptor Agonist Market - Global Forecast 2025-2030

  • PDF Icon

    Report

  • 186 Pages
  • August 2025
  • Region: Global
  • 360iResearch™
  • ID: 5533031
UP TO OFF until Jan 01st 2026
1h Free Analyst Time
Description Jump to:
1h Free Analyst Time

Speak directly to the analyst to clarify any post sales queries you may have.

The GLP-1 Receptor Agonist Market is experiencing accelerated innovation and reshaping therapeutic and commercial strategies worldwide. With expanding applications and improved patient outcomes, this sector presents compelling opportunities for industry leaders to optimize value across multiple care pathways.

Market Snapshot: GLP-1 Receptor Agonist Market Growth Overview

The GLP-1 Receptor Agonist Market grew from USD 40.31 billion in 2024 to USD 45.59 billion in 2025. It is expected to continue growing at a CAGR of 13.36%, reaching USD 85.55 billion by 2030. Strong underlying demand is supported by ongoing clinical adoption in diabetes, obesity, and cardiometabolic care, as well as the introduction of innovative formulations and delivery systems. Expedited regulatory pathways for oral and combination therapies are accelerating market traction, while healthcare payers and providers increasingly value these therapies for their broader risk management benefits.

Scope & Segmentation

This report comprehensively addresses the extensive spectrum of the GLP-1 receptor agonist landscape to support tailored business planning and market engagement:

  • Drug Classes: Dulaglutide; Liraglutide; Semaglutide
  • Drug Types: Long-Acting Agonists; Short-Acting Agonists
  • Route of Administration: Oral; Parenteral
  • Applications: Cardiovascular Health; Diabetes Management; Weight Management
  • Distribution Channels: Hospital Pharmacies; Online Pharmacies; Retail Pharmacies
  • Geographies: Americas (including United States—California, Texas, New York, Florida, Illinois, Pennsylvania, Ohio—Canada, Mexico, Brazil, Argentina); Europe, Middle East & Africa (including United Kingdom, Germany, France, Russia, Italy, Spain, United Arab Emirates, Saudi Arabia, South Africa, Denmark, Netherlands, Qatar, Finland, Sweden, Nigeria, Egypt, Turkey, Israel, Norway, Poland, Switzerland); Asia-Pacific (including China, India, Japan, Australia, South Korea, Indonesia, Thailand, Philippines, Malaysia, Singapore, Vietnam, Taiwan)
  • Key Industry Players: Eli Lilly and Company, Sanofi, Novo-Nordisk A/S, AstraZeneca, Pfizer Inc., Amgen Inc., Innovent Biologics Inc., PegBio Co. Ltd., Sun Pharmaceutical Industries Ltd., Boehringer Ingelheim International GmbH

Key Takeaways for Decision-Makers

  • Emerging oral formulations and extended-release technologies are redefining patient adherence and market differentiation within GLP-1 receptor agonists.
  • Strategic investments in research alliances are driving the pipeline of next-generation agents targeting broader indications, including combinatorial therapies.
  • Regional differences in reimbursement structures and regulatory environments create the need for differentiated market access and commercialization strategies.
  • Shifting payer models increasingly reward therapies evidencing both cost-effectiveness and mitigation of long-term complications in cardiometabolic disorders.
  • Real-world data and digital health integrations are empowering tighter monitoring of adherence and outcomes, leading to optimized dosing and patient engagement.
  • Lifecycle management, patent positioning, and biosimilar preparedness remain critical for maintaining competitive advantage as market exclusivity horizons shift.

Tariff Impact in the United States

Recent tariff changes in 2025 have altered the U.S. environment for GLP-1 receptor agonist market participants. Adjustments in import duties have affected supply chain strategies, encouraging a pivot to domestic sourcing and increased investment in local manufacturing. As a result, payers advocate for cost transparency and manufacturers adapt patient access initiatives to offset incremental pricing pressures. Enhanced collaboration among stakeholders supports continuity and shields value chains from prospective regulatory changes.

Methodology & Data Sources

This report leverages a robust research methodology, integrating primary interviews with endocrinologists, cardiologists, and supply chain experts, as well as a comprehensive literature review of clinical trials and regulatory filings. Real-world claims and registry data inform segment analysis, while cross-referencing and local expert consultations ensure reliability across global regions.

Why This Report Matters

  • Enables senior leaders to benchmark against industry trends, anticipate regulatory pivots, and structure investments proactively.
  • Supports development of region-specific market entry, pricing, and partnership strategies for sustainable long-term growth.
  • Equips decision-makers to evaluate portfolio opportunities, accelerate innovation, and align with payer and provider requirements in dynamic care environments.

Conclusion

The GLP-1 Receptor Agonist Market delivers actionable insights for strategic planning amid complex innovation, regulatory, and payer landscapes. Business leaders can use this intelligence to inform growth strategies and operational priorities during a period of meaningful market evolution.

 

Additional Product Information:

  • Purchase of this report includes 1 year online access with quarterly updates.
  • This report can be updated on request. Please contact our Customer Experience team using the Ask a Question widget on our website.

Table of Contents

1. Preface
1.1. Objectives of the Study
1.2. Market Segmentation & Coverage
1.3. Years Considered for the Study
1.4. Currency & Pricing
1.5. Language
1.6. Stakeholders
2. Research Methodology
2.1. Define: Research Objective
2.2. Determine: Research Design
2.3. Prepare: Research Instrument
2.4. Collect: Data Source
2.5. Analyze: Data Interpretation
2.6. Formulate: Data Verification
2.7. Publish: Research Report
2.8. Repeat: Report Update
3. Executive Summary
4. Market Overview
4.1. Introduction
4.2. Market Sizing & Forecasting
5. Market Dynamics
5.1. Emergence of oral small-molecule GLP-1 receptor agonists addressing patient adherence challenges and expanding market access
5.2. Rapid adoption of combination therapies pairing GLP-1 agonists with SGLT2 inhibitors for enhanced glycemic control in type 2 diabetes
5.3. Intensification of real-world evidence generation demonstrating cardiovascular benefits of GLP-1 receptor agonists beyond glycemic outcomes
5.4. Development of next-generation GLP-1 analogs with prolonged half-life and reduced injection frequency for improved patient compliance
6. Market Insights
6.1. Porter’s Five Forces Analysis
6.2. PESTLE Analysis
7. Cumulative Impact of United States Tariffs 2025
8. GLP-1 Receptor Agonist Market, by Drug Class
8.1. Introduction
8.2. Dulaglutide
8.3. Liraglutide
8.4. Semaglutide
9. GLP-1 Receptor Agonist Market, by Drug Type
9.1. Introduction
9.2. Long-Acting Agonists
9.3. Short-Acting Agonists
10. GLP-1 Receptor Agonist Market, by Route of Administration
10.1. Introduction
10.2. Oral
10.3. Parenteral
11. GLP-1 Receptor Agonist Market, by Application
11.1. Introduction
11.2. Cardiovascular Health
11.3. Diabetes Management
11.4. Weight Management
12. GLP-1 Receptor Agonist Market, by Distribution Channel
12.1. Introduction
12.2. Hospital Pharmacies
12.3. Online Pharmacies
12.4. Retail Pharmacies
13. Americas GLP-1 Receptor Agonist Market
13.1. Introduction
13.2. United States
13.3. Canada
13.4. Mexico
13.5. Brazil
13.6. Argentina
14. Europe, Middle East & Africa GLP-1 Receptor Agonist Market
14.1. Introduction
14.2. United Kingdom
14.3. Germany
14.4. France
14.5. Russia
14.6. Italy
14.7. Spain
14.8. United Arab Emirates
14.9. Saudi Arabia
14.10. South Africa
14.11. Denmark
14.12. Netherlands
14.13. Qatar
14.14. Finland
14.15. Sweden
14.16. Nigeria
14.17. Egypt
14.18. Turkey
14.19. Israel
14.20. Norway
14.21. Poland
14.22. Switzerland
15. Asia-Pacific GLP-1 Receptor Agonist Market
15.1. Introduction
15.2. China
15.3. India
15.4. Japan
15.5. Australia
15.6. South Korea
15.7. Indonesia
15.8. Thailand
15.9. Philippines
15.10. Malaysia
15.11. Singapore
15.12. Vietnam
15.13. Taiwan
16. Competitive Landscape
16.1. Market Share Analysis, 2024
16.2. FPNV Positioning Matrix, 2024
16.3. Competitive Analysis
16.3.1. Eli Lilly and Company
16.3.2. Sanofi
16.3.3. Novo-Nordisk A/S
16.3.4. AstraZeneca
16.3.5. Pfizer.Inc
16.3.6. Amgen, Inc.
16.3.7. Innovent Biologics, Inc.
16.3.8. PegBio Co., Ltd.
16.3.9. Sun Pharmaceutical Industries Ltd.
16.3.10. Boehringer Ingelheim International GmbH
17. ResearchAI
18. ResearchStatistics
19. ResearchContacts
20. ResearchArticles
21. Appendix
List of Figures
FIGURE 1. GLP-1 RECEPTOR AGONIST MARKET RESEARCH PROCESS
FIGURE 2. GLOBAL GLP-1 RECEPTOR AGONIST MARKET SIZE, 2018-2030 (USD MILLION)
FIGURE 3. GLOBAL GLP-1 RECEPTOR AGONIST MARKET SIZE, BY REGION, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 4. GLOBAL GLP-1 RECEPTOR AGONIST MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 5. GLOBAL GLP-1 RECEPTOR AGONIST MARKET SIZE, BY DRUG CLASS, 2024 VS 2030 (%)
FIGURE 6. GLOBAL GLP-1 RECEPTOR AGONIST MARKET SIZE, BY DRUG CLASS, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 7. GLOBAL GLP-1 RECEPTOR AGONIST MARKET SIZE, BY DRUG TYPE, 2024 VS 2030 (%)
FIGURE 8. GLOBAL GLP-1 RECEPTOR AGONIST MARKET SIZE, BY DRUG TYPE, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 9. GLOBAL GLP-1 RECEPTOR AGONIST MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2024 VS 2030 (%)
FIGURE 10. GLOBAL GLP-1 RECEPTOR AGONIST MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 11. GLOBAL GLP-1 RECEPTOR AGONIST MARKET SIZE, BY APPLICATION, 2024 VS 2030 (%)
FIGURE 12. GLOBAL GLP-1 RECEPTOR AGONIST MARKET SIZE, BY APPLICATION, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 13. GLOBAL GLP-1 RECEPTOR AGONIST MARKET SIZE, BY DISTRIBUTION CHANNEL, 2024 VS 2030 (%)
FIGURE 14. GLOBAL GLP-1 RECEPTOR AGONIST MARKET SIZE, BY DISTRIBUTION CHANNEL, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 15. AMERICAS GLP-1 RECEPTOR AGONIST MARKET SIZE, BY COUNTRY, 2024 VS 2030 (%)
FIGURE 16. AMERICAS GLP-1 RECEPTOR AGONIST MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 17. UNITED STATES GLP-1 RECEPTOR AGONIST MARKET SIZE, BY STATE, 2024 VS 2030 (%)
FIGURE 18. UNITED STATES GLP-1 RECEPTOR AGONIST MARKET SIZE, BY STATE, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 19. EUROPE, MIDDLE EAST & AFRICA GLP-1 RECEPTOR AGONIST MARKET SIZE, BY COUNTRY, 2024 VS 2030 (%)
FIGURE 20. EUROPE, MIDDLE EAST & AFRICA GLP-1 RECEPTOR AGONIST MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 21. ASIA-PACIFIC GLP-1 RECEPTOR AGONIST MARKET SIZE, BY COUNTRY, 2024 VS 2030 (%)
FIGURE 22. ASIA-PACIFIC GLP-1 RECEPTOR AGONIST MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 23. GLP-1 RECEPTOR AGONIST MARKET SHARE, BY KEY PLAYER, 2024
FIGURE 24. GLP-1 RECEPTOR AGONIST MARKET, FPNV POSITIONING MATRIX, 2024
FIGURE 25. GLP-1 RECEPTOR AGONIST MARKET: RESEARCHAI
FIGURE 26. GLP-1 RECEPTOR AGONIST MARKET: RESEARCHSTATISTICS
FIGURE 27. GLP-1 RECEPTOR AGONIST MARKET: RESEARCHCONTACTS
FIGURE 28. GLP-1 RECEPTOR AGONIST MARKET: RESEARCHARTICLES
List of Tables
TABLE 1. GLP-1 RECEPTOR AGONIST MARKET SEGMENTATION & COVERAGE
TABLE 2. UNITED STATES DOLLAR EXCHANGE RATE, 2018-2024
TABLE 3. GLOBAL GLP-1 RECEPTOR AGONIST MARKET SIZE, 2018-2024 (USD MILLION)
TABLE 4. GLOBAL GLP-1 RECEPTOR AGONIST MARKET SIZE, 2025-2030 (USD MILLION)
TABLE 5. GLOBAL GLP-1 RECEPTOR AGONIST MARKET SIZE, BY REGION, 2018-2024 (USD MILLION)
TABLE 6. GLOBAL GLP-1 RECEPTOR AGONIST MARKET SIZE, BY REGION, 2025-2030 (USD MILLION)
TABLE 7. GLOBAL GLP-1 RECEPTOR AGONIST MARKET SIZE, BY COUNTRY, 2018-2024 (USD MILLION)
TABLE 8. GLOBAL GLP-1 RECEPTOR AGONIST MARKET SIZE, BY COUNTRY, 2025-2030 (USD MILLION)
TABLE 9. GLOBAL GLP-1 RECEPTOR AGONIST MARKET SIZE, BY DRUG CLASS, 2018-2024 (USD MILLION)
TABLE 10. GLOBAL GLP-1 RECEPTOR AGONIST MARKET SIZE, BY DRUG CLASS, 2025-2030 (USD MILLION)
TABLE 11. GLOBAL GLP-1 RECEPTOR AGONIST MARKET SIZE, BY DULAGLUTIDE, BY REGION, 2018-2024 (USD MILLION)
TABLE 12. GLOBAL GLP-1 RECEPTOR AGONIST MARKET SIZE, BY DULAGLUTIDE, BY REGION, 2025-2030 (USD MILLION)
TABLE 13. GLOBAL GLP-1 RECEPTOR AGONIST MARKET SIZE, BY LIRAGLUTIDE, BY REGION, 2018-2024 (USD MILLION)
TABLE 14. GLOBAL GLP-1 RECEPTOR AGONIST MARKET SIZE, BY LIRAGLUTIDE, BY REGION, 2025-2030 (USD MILLION)
TABLE 15. GLOBAL GLP-1 RECEPTOR AGONIST MARKET SIZE, BY SEMAGLUTIDE, BY REGION, 2018-2024 (USD MILLION)
TABLE 16. GLOBAL GLP-1 RECEPTOR AGONIST MARKET SIZE, BY SEMAGLUTIDE, BY REGION, 2025-2030 (USD MILLION)
TABLE 17. GLOBAL GLP-1 RECEPTOR AGONIST MARKET SIZE, BY DRUG TYPE, 2018-2024 (USD MILLION)
TABLE 18. GLOBAL GLP-1 RECEPTOR AGONIST MARKET SIZE, BY DRUG TYPE, 2025-2030 (USD MILLION)
TABLE 19. GLOBAL GLP-1 RECEPTOR AGONIST MARKET SIZE, BY LONG-ACTING AGONISTS, BY REGION, 2018-2024 (USD MILLION)
TABLE 20. GLOBAL GLP-1 RECEPTOR AGONIST MARKET SIZE, BY LONG-ACTING AGONISTS, BY REGION, 2025-2030 (USD MILLION)
TABLE 21. GLOBAL GLP-1 RECEPTOR AGONIST MARKET SIZE, BY SHORT-ACTING AGONISTS, BY REGION, 2018-2024 (USD MILLION)
TABLE 22. GLOBAL GLP-1 RECEPTOR AGONIST MARKET SIZE, BY SHORT-ACTING AGONISTS, BY REGION, 2025-2030 (USD MILLION)
TABLE 23. GLOBAL GLP-1 RECEPTOR AGONIST MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2024 (USD MILLION)
TABLE 24. GLOBAL GLP-1 RECEPTOR AGONIST MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2025-2030 (USD MILLION)
TABLE 25. GLOBAL GLP-1 RECEPTOR AGONIST MARKET SIZE, BY ORAL, BY REGION, 2018-2024 (USD MILLION)
TABLE 26. GLOBAL GLP-1 RECEPTOR AGONIST MARKET SIZE, BY ORAL, BY REGION, 2025-2030 (USD MILLION)
TABLE 27. GLOBAL GLP-1 RECEPTOR AGONIST MARKET SIZE, BY PARENTERAL, BY REGION, 2018-2024 (USD MILLION)
TABLE 28. GLOBAL GLP-1 RECEPTOR AGONIST MARKET SIZE, BY PARENTERAL, BY REGION, 2025-2030 (USD MILLION)
TABLE 29. GLOBAL GLP-1 RECEPTOR AGONIST MARKET SIZE, BY APPLICATION, 2018-2024 (USD MILLION)
TABLE 30. GLOBAL GLP-1 RECEPTOR AGONIST MARKET SIZE, BY APPLICATION, 2025-2030 (USD MILLION)
TABLE 31. GLOBAL GLP-1 RECEPTOR AGONIST MARKET SIZE, BY CARDIOVASCULAR HEALTH, BY REGION, 2018-2024 (USD MILLION)
TABLE 32. GLOBAL GLP-1 RECEPTOR AGONIST MARKET SIZE, BY CARDIOVASCULAR HEALTH, BY REGION, 2025-2030 (USD MILLION)
TABLE 33. GLOBAL GLP-1 RECEPTOR AGONIST MARKET SIZE, BY DIABETES MANAGEMENT, BY REGION, 2018-2024 (USD MILLION)
TABLE 34. GLOBAL GLP-1 RECEPTOR AGONIST MARKET SIZE, BY DIABETES MANAGEMENT, BY REGION, 2025-2030 (USD MILLION)
TABLE 35. GLOBAL GLP-1 RECEPTOR AGONIST MARKET SIZE, BY WEIGHT MANAGEMENT, BY REGION, 2018-2024 (USD MILLION)
TABLE 36. GLOBAL GLP-1 RECEPTOR AGONIST MARKET SIZE, BY WEIGHT MANAGEMENT, BY REGION, 2025-2030 (USD MILLION)
TABLE 37. GLOBAL GLP-1 RECEPTOR AGONIST MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2024 (USD MILLION)
TABLE 38. GLOBAL GLP-1 RECEPTOR AGONIST MARKET SIZE, BY DISTRIBUTION CHANNEL, 2025-2030 (USD MILLION)
TABLE 39. GLOBAL GLP-1 RECEPTOR AGONIST MARKET SIZE, BY HOSPITAL PHARMACIES, BY REGION, 2018-2024 (USD MILLION)
TABLE 40. GLOBAL GLP-1 RECEPTOR AGONIST MARKET SIZE, BY HOSPITAL PHARMACIES, BY REGION, 2025-2030 (USD MILLION)
TABLE 41. GLOBAL GLP-1 RECEPTOR AGONIST MARKET SIZE, BY ONLINE PHARMACIES, BY REGION, 2018-2024 (USD MILLION)
TABLE 42. GLOBAL GLP-1 RECEPTOR AGONIST MARKET SIZE, BY ONLINE PHARMACIES, BY REGION, 2025-2030 (USD MILLION)
TABLE 43. GLOBAL GLP-1 RECEPTOR AGONIST MARKET SIZE, BY RETAIL PHARMACIES, BY REGION, 2018-2024 (USD MILLION)
TABLE 44. GLOBAL GLP-1 RECEPTOR AGONIST MARKET SIZE, BY RETAIL PHARMACIES, BY REGION, 2025-2030 (USD MILLION)
TABLE 45. AMERICAS GLP-1 RECEPTOR AGONIST MARKET SIZE, BY DRUG CLASS, 2018-2024 (USD MILLION)
TABLE 46. AMERICAS GLP-1 RECEPTOR AGONIST MARKET SIZE, BY DRUG CLASS, 2025-2030 (USD MILLION)
TABLE 47. AMERICAS GLP-1 RECEPTOR AGONIST MARKET SIZE, BY DRUG TYPE, 2018-2024 (USD MILLION)
TABLE 48. AMERICAS GLP-1 RECEPTOR AGONIST MARKET SIZE, BY DRUG TYPE, 2025-2030 (USD MILLION)
TABLE 49. AMERICAS GLP-1 RECEPTOR AGONIST MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2024 (USD MILLION)
TABLE 50. AMERICAS GLP-1 RECEPTOR AGONIST MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2025-2030 (USD MILLION)
TABLE 51. AMERICAS GLP-1 RECEPTOR AGONIST MARKET SIZE, BY APPLICATION, 2018-2024 (USD MILLION)
TABLE 52. AMERICAS GLP-1 RECEPTOR AGONIST MARKET SIZE, BY APPLICATION, 2025-2030 (USD MILLION)
TABLE 53. AMERICAS GLP-1 RECEPTOR AGONIST MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2024 (USD MILLION)
TABLE 54. AMERICAS GLP-1 RECEPTOR AGONIST MARKET SIZE, BY DISTRIBUTION CHANNEL, 2025-2030 (USD MILLION)
TABLE 55. AMERICAS GLP-1 RECEPTOR AGONIST MARKET SIZE, BY COUNTRY, 2018-2024 (USD MILLION)
TABLE 56. AMERICAS GLP-1 RECEPTOR AGONIST MARKET SIZE, BY COUNTRY, 2025-2030 (USD MILLION)
TABLE 57. UNITED STATES GLP-1 RECEPTOR AGONIST MARKET SIZE, BY DRUG CLASS, 2018-2024 (USD MILLION)
TABLE 58. UNITED STATES GLP-1 RECEPTOR AGONIST MARKET SIZE, BY DRUG CLASS, 2025-2030 (USD MILLION)
TABLE 59. UNITED STATES GLP-1 RECEPTOR AGONIST MARKET SIZE, BY DRUG TYPE, 2018-2024 (USD MILLION)
TABLE 60. UNITED STATES GLP-1 RECEPTOR AGONIST MARKET SIZE, BY DRUG TYPE, 2025-2030 (USD MILLION)
TABLE 61. UNITED STATES GLP-1 RECEPTOR AGONIST MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2024 (USD MILLION)
TABLE 62. UNITED STATES GLP-1 RECEPTOR AGONIST MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2025-2030 (USD MILLION)
TABLE 63. UNITED STATES GLP-1 RECEPTOR AGONIST MARKET SIZE, BY APPLICATION, 2018-2024 (USD MILLION)
TABLE 64. UNITED STATES GLP-1 RECEPTOR AGONIST MARKET SIZE, BY APPLICATION, 2025-2030 (USD MILLION)
TABLE 65. UNITED STATES GLP-1 RECEPTOR AGONIST MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2024 (USD MILLION)
TABLE 66. UNITED STATES GLP-1 RECEPTOR AGONIST MARKET SIZE, BY DISTRIBUTION CHANNEL, 2025-2030 (USD MILLION)
TABLE 67. UNITED STATES GLP-1 RECEPTOR AGONIST MARKET SIZE, BY STATE, 2018-2024 (USD MILLION)
TABLE 68. UNITED STATES GLP-1 RECEPTOR AGONIST MARKET SIZE, BY STATE, 2025-2030 (USD MILLION)
TABLE 69. CANADA GLP-1 RECEPTOR AGONIST MARKET SIZE, BY DRUG CLASS, 2018-2024 (USD MILLION)
TABLE 70. CANADA GLP-1 RECEPTOR AGONIST MARKET SIZE, BY DRUG CLASS, 2025-2030 (USD MILLION)
TABLE 71. CANADA GLP-1 RECEPTOR AGONIST MARKET SIZE, BY DRUG TYPE, 2018-2024 (USD MILLION)
TABLE 72. CANADA GLP-1 RECEPTOR AGONIST MARKET SIZE, BY DRUG TYPE, 2025-2030 (USD MILLION)
TABLE 73. CANADA GLP-1 RECEPTOR AGONIST MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2024 (USD MILLION)
TABLE 74. CANADA GLP-1 RECEPTOR AGONIST MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2025-2030 (USD MILLION)
TABLE 75. CANADA GLP-1 RECEPTOR AGONIST MARKET SIZE, BY APPLICATION, 2018-2024 (USD MILLION)
TABLE 76. CANADA GLP-1 RECEPTOR AGONIST MARKET SIZE, BY APPLICATION, 2025-2030 (USD MILLION)
TABLE 77. CANADA GLP-1 RECEPTOR AGONIST MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2024 (USD MILLION)
TABLE 78. CANADA GLP-1 RECEPTOR AGONIST MARKET SIZE, BY DISTRIBUTION CHANNEL, 2025-2030 (USD MILLION)
TABLE 79. MEXICO GLP-1 RECEPTOR AGONIST MARKET SIZE, BY DRUG CLASS, 2018-2024 (USD MILLION)
TABLE 80. MEXICO GLP-1 RECEPTOR AGONIST MARKET SIZE, BY DRUG CLASS, 2025-2030 (USD MILLION)
TABLE 81. MEXICO GLP-1 RECEPTOR AGONIST MARKET SIZE, BY DRUG TYPE, 2018-2024 (USD MILLION)
TABLE 82. MEXICO GLP-1 RECEPTOR AGONIST MARKET SIZE, BY DRUG TYPE, 2025-2030 (USD MILLION)
TABLE 83. MEXICO GLP-1 RECEPTOR AGONIST MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2024 (USD MILLION)
TABLE 84. MEXICO GLP-1 RECEPTOR AGONIST MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2025-2030 (USD MILLION)
TABLE 85. MEXICO GLP-1 RECEPTOR AGONIST MARKET SIZE, BY APPLICATION, 2018-2024 (USD MILLION)
TABLE 86. MEXICO GLP-1 RECEPTOR AGONIST MARKET SIZE, BY APPLICATION, 2025-2030 (USD MILLION)
TABLE 87. MEXICO GLP-1 RECEPTOR AGONIST MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2024 (USD MILLION)
TABLE 88. MEXICO GLP-1 RECEPTOR AGONIST MARKET SIZE, BY DISTRIBUTION CHANNEL, 2025-2030 (USD MILLION)
TABLE 89. BRAZIL GLP-1 RECEPTOR AGONIST MARKET SIZE, BY DRUG CLASS, 2018-2024 (USD MILLION)
TABLE 90. BRAZIL GLP-1 RECEPTOR AGONIST MARKET SIZE, BY DRUG CLASS, 2025-2030 (USD MILLION)
TABLE 91. BRAZIL GLP-1 RECEPTOR AGONIST MARKET SIZE, BY DRUG TYPE, 2018-2024 (USD MILLION)
TABLE 92. BRAZIL GLP-1 RECEPTOR AGONIST MARKET SIZE, BY DRUG TYPE, 2025-2030 (USD MILLION)
TABLE 93. BRAZIL GLP-1 RECEPTOR AGONIST MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2024 (USD MILLION)
TABLE 94. BRAZIL GLP-1 RECEPTOR AGONIST MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2025-2030 (USD MILLION)
TABLE 95. BRAZIL GLP-1 RECEPTOR AGONIST MARKET SIZE, BY APPLICATION, 2018-2024 (USD MILLION)
TABLE 96. BRAZIL GLP-1 RECEPTOR AGONIST MARKET SIZE, BY APPLICATION, 2025-2030 (USD MILLION)
TABLE 97. BRAZIL GLP-1 RECEPTOR AGONIST MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2024 (USD MILLION)
TABLE 98. BRAZIL GLP-1 RECEPTOR AGONIST MARKET SIZE, BY DISTRIBUTION CHANNEL, 2025-2030 (USD MILLION)
TABLE 99. ARGENTINA GLP-1 RECEPTOR AGONIST MARKET SIZE, BY DRUG CLASS, 2018-2024 (USD MILLION)
TABLE 100. ARGENTINA GLP-1 RECEPTOR AGONIST MARKET SIZE, BY DRUG CLASS, 2025-2030 (USD MILLION)
TABLE 101. ARGENTINA GLP-1 RECEPTOR AGONIST MARKET SIZE, BY DRUG TYPE, 2018-2024 (USD MILLION)
TABLE 102. ARGENTINA GLP-1 RECEPTOR AGONIST MARKET SIZE, BY DRUG TYPE, 2025-2030 (USD MILLION)
TABLE 103. ARGENTINA GLP-1 RECEPTOR AGONIST MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2024 (USD MILLION)
TABLE 104. ARGENTINA GLP-1 RECEPTOR AGONIST MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2025-2030 (USD MILLION)
TABLE 105. ARGENTINA GLP-1 RECEPTOR AGONIST MARKET SIZE, BY APPLICATION, 2018-2024 (USD MILLION)
TABLE 106. ARGENTINA GLP-1 RECEPTOR AGONIST MARKET SIZE, BY APPLICATION, 2025-2030 (USD MILLION)
TABLE 107. ARGENTINA GLP-1 RECEPTOR AGONIST MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2024 (USD MILLION)
TABLE 108. ARGENTINA GLP-1 RECEPTOR AGONIST MARKET SIZE, BY DISTRIBUTION CHANNEL, 2025-2030 (USD MILLION)
TABLE 109. EUROPE, MIDDLE EAST & AFRICA GLP-1 RECEPTOR AGONIST MARKET SIZE, BY DRUG CLASS, 2018-2024 (USD MILLION)
TABLE 110. EUROPE, MIDDLE EAST & AFRICA GLP-1 RECEPTOR AGONIST MARKET SIZE, BY DRUG CLASS, 2025-2030 (USD MILLION)
TABLE 111. EUROPE, MIDDLE EAST & AFRICA GLP-1 RECEPTOR AGONIST MARKET SIZE, BY DRUG TYPE, 2018-2024 (USD MILLION)
TABLE 112. EUROPE, MIDDLE EAST & AFRICA GLP-1 RECEPTOR AGONIST MARKET SIZE, BY DRUG TYPE, 2025-2030 (USD MILLION)
TABLE 113. EUROPE, MIDDLE EAST & AFRICA GLP-1 RECEPTOR AGONIST MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2024 (USD MILLION)
TABLE 114. EUROPE, MIDDLE EAST & AFRICA GLP-1 RECEPTOR AGONIST MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2025-2030 (USD MILLION)
TABLE 115. EUROPE, MIDDLE EAST & AFRICA GLP-1 RECEPTOR AGONIST MARKET SIZE, BY APPLICATION, 2018-2024 (USD MILLION)
TABLE 116. EUROPE, MIDDLE EAST & AFRICA GLP-1 RECEPTOR AGONIST MARKET SIZE, BY APPLICATION, 2025-2030 (USD MILLION)
TABLE 117. EUROPE, MIDDLE EAST & AFRICA GLP-1 RECEPTOR AGONIST MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2024 (USD MILLION)
TABLE 118. EUROPE, MIDDLE EAST & AFRICA GLP-1 RECEPTOR AGONIST MARKET SIZE, BY DISTRIBUTION CHANNEL, 2025-2030 (USD MILLION)
TABLE 119. EUROPE, MIDDLE EAST & AFRICA GLP-1 RECEPTOR AGONIST MARKET SIZE, BY COUNTRY, 2018-2024 (USD MILLION)
TABLE 120. EUROPE, MIDDLE EAST & AFRICA GLP-1 RECEPTOR AGONIST MARKET SIZE, BY COUNTRY, 2025-2030 (USD MILLION)
TABLE 121. UNITED KINGDOM GLP-1 RECEPTOR AGONIST MARKET SIZE, BY DRUG CLASS, 2018-2024 (USD MILLION)
TABLE 122. UNITED KINGDOM GLP-1 RECEPTOR AGONIST MARKET SIZE, BY DRUG CLASS, 2025-2030 (USD MILLION)
TABLE 123. UNITED KINGDOM GLP-1 RECEPTOR AGONIST MARKET SIZE, BY DRUG TYPE, 2018-2024 (USD MILLION)
TABLE 124. UNITED KINGDOM GLP-1 RECEPTOR AGONIST MARKET SIZE, BY DRUG TYPE, 2025-2030 (USD MILLION)
TABLE 125. UNITED KINGDOM GLP-1 RECEPTOR AGONIST MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2024 (USD MILLION)
TABLE 126. UNITED KINGDOM GLP-1 RECEPTOR AGONIST MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2025-2030 (USD MILLION)
TABLE 127. UNITED KINGDOM GLP-1 RECEPTOR AGONIST MARKET SIZE, BY APPLICATION, 2018-2024 (USD MILLION)
TABLE 128. UNITED KINGDOM GLP-1 RECEPTOR AGONIST MARKET SIZE, BY APPLICATION, 2025-2030 (USD MILLION)
TABLE 129. UNITED KINGDOM GLP-1 RECEPTOR AGONIST MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2024 (USD MILLION)
TABLE 130. UNITED KINGDOM GLP-1 RECEPTOR AGONIST MARKET SIZE, BY DISTRIBUTION CHANNEL, 2025-2030 (USD MILLION)
TABLE 131. GERMANY GLP-1 RECEPTOR AGONIST MARKET SIZE, BY DRUG CLASS, 2018-2024 (USD MILLION)
TABLE 132. GERMANY GLP-1 RECEPTOR AGONIST MARKET SIZE, BY DRUG CLASS, 2025-2030 (USD MILLION)
TABLE 133. GERMANY GLP-1 RECEPTOR AGONIST MARKET SIZE, BY DRUG TYPE, 2018-2024 (USD MILLION)
TABLE 134. GERMANY GLP-1 RECEPTOR AGONIST MARKET SIZE, BY DRUG TYPE, 2025-2030 (USD MILLION)
TABLE 135. GERMANY GLP-1 RECEPTOR AGONIST MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2024 (USD MILLION)
TABLE 136. GERMANY GLP-1 RECEPTOR AGONIST MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2025-2030 (USD MILLION)
TABLE 137. GERMANY GLP-1 RECEPTOR AGONIST MARKET SIZE, BY APPLICATION, 2018-2024 (USD MILLION)
TABLE 138. GERMANY GLP-1 RECEPTOR AGONIST MARKET SIZE, BY APPLICATION, 2025-2030 (USD MILLION)
TABLE 139. GERMANY GLP-1 RECEPTOR AGONIST MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2024 (USD MILLION)
TABLE 140. GERMANY GLP-1 RECEPTOR AGONIST MARKET SIZE, BY DISTRIBUTION CHANNEL, 2025-2030 (USD MILLION)
TABLE 141. FRANCE GLP-1 RECEPTOR AGONIST MARKET SIZE, BY DRUG CLASS, 2018-2024 (USD MILLION)
TABLE 142. FRANCE GLP-1 RECEPTOR AGONIST MARKET SIZE, BY DRUG CLASS, 2025-2030 (USD MILLION)
TABLE 143. FRANCE GLP-1 RECEPTOR AGONIST MARKET SIZE, BY DRUG TYPE, 2018-2024 (USD MILLION)
TABLE 144. FRANCE GLP-1 RECEPTOR AGONIST MARKET SIZE, BY DRUG TYPE, 2025-2030 (USD MILLION)
TABLE 145. FRANCE GLP-1 RECEPTOR AGONIST MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2024 (USD MILLION)
TABLE 146. FRANCE GLP-1 RECEPTOR AGONIST MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2025-2030 (USD MILLION)
TABLE 147. FRANCE GLP-1 RECEPTOR AGONIST MARKET SIZE, BY APPLICATION, 2018-2024 (USD MILLION)
TABLE 148. FRANCE GLP-1 RECEPTOR AGONIST MARKET SIZE, BY APPLICATION, 2025-2030 (USD MILLION)
TABLE 149. FRANCE GLP-1 RECEPTOR AGONIST MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2024 (USD MILLION)
TABLE 150. FRANCE GLP-1 RECEPTOR AGONIST MARKET SIZE, BY DISTRIBUTION CHANNEL, 2025-2030 (USD MILLION)
TABLE 151. RUSSIA GLP-1 RECEPTOR AGONIST MARKET SIZE, BY DRUG CLASS, 2018-2024 (USD MILLION)
TABLE 152. RUSSIA GLP-1 RECEPTOR AGONIST MARKET SIZE, BY DRUG CLASS, 2025-2030 (USD MILLION)
TABLE 153. RUSSIA GLP-1 RECEPTOR AGONIST MARKET SIZE, BY DRUG TYPE, 2018-2024 (USD MILLION)
TABLE 154. RUSSIA GLP-1 RECEPTOR AGONIST MARKET SIZE, BY DRUG TYPE, 2025-2030 (USD MILLION)
TABLE 155. RUSSIA GLP-1 RECEPTOR AGONIST MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2024 (USD MILLION)
TABLE 156. RUSSIA GLP-1 RECEPTOR AGONIST MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2025-2030 (USD MILLION)
TABLE 157. RUSSIA GLP-1 RECEPTOR AGONIST MARKET SIZE, BY APPLICATION, 2018-2024 (USD MILLION)
TABLE 158. RUSSIA GLP-1 RECEPTOR AGONIST MARKET SIZE, BY APPLICATION, 2025-2030 (USD MILLION)
TABLE 159. RUSSIA GLP-1 RECEPTOR AGONIST MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2024 (USD MILLION)
TABLE 160. RUSSIA GLP-1 RECEPTOR AGONIST MARKET SIZE, BY DISTRIBUTION CHANNEL, 2025-2030 (USD MILLION)
TABLE 161. ITALY GLP-1 RECEPTOR AGONIST MARKET SIZE, BY DRUG CLASS, 2018-2024 (USD MILLION)
TABLE 162. ITALY GLP-1 RECEPTOR AGONIST MARKET SIZE, BY DRUG CLASS, 2025-2030 (USD MILLION)
TABLE 163. ITALY GLP-1 RECEPTOR AGONIST MARKET SIZE, BY DRUG TYPE, 2018-2024 (USD MILLION)
TABLE 164. ITALY GLP-1 RECEPTOR AGONIST MARKET SIZE, BY DRUG TYPE, 2025-2030 (USD MILLION)
TABLE 165. ITALY GLP-1 RECEPTOR AGONIST MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2024 (USD MILLION)
TABLE 166. ITALY GLP-1 RECEPTOR AGONIST MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2025-2030 (USD MILLION)
TABLE 167. ITALY GLP-1 RECEPTOR AGONIST MARKET SIZE, BY APPLICATION, 2018-2024 (USD MILLION)
TABLE 168. ITALY GLP-1 RECEPTOR AGONIST MARKET SIZE, BY APPLICATION, 2025-2030 (USD MILLION)
TABLE 169. ITALY GLP-1 RECEPTOR AGONIST MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2024 (USD MILLION)
TABLE 170. ITALY GLP-1 RECEPTOR AGONIST MARKET SIZE, BY DISTRIBUTION CHANNEL, 2025-2030 (USD MILLION)
TABLE 171. SPAIN GLP-1 RECEPTOR AGONIST MARKET SIZE, BY DRUG CLASS, 2018-2024 (USD MILLION)
TABLE 172. SPAIN GLP-1 RECEPTOR AGONIST MARKET SIZE, BY DRUG CLASS, 2025-2030 (USD MILLION)
TABLE 173. SPAIN GLP-1 RECEPTOR AGONIST MARKET SIZE, BY DRUG TYPE, 2018-2024 (USD MILLION)
TABLE 174. SPAIN GLP-1 RECEPTOR AGONIST MARKET SIZE, BY DRUG TYPE, 2025-2030 (USD MILLION)
TABLE 175. SPAIN GLP-1 RECEPTOR AGONIST MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2024 (USD MILLION)
TABLE 176. SPAIN GLP-1 RECEPTOR AGONIST MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2025-2030 (USD MILLION)
TABLE 177. SPAIN GLP-1 RECEPTOR AGONIST MARKET SIZE, BY APPLICATION, 2018-2024 (USD MILLION)
TABLE 178. SPAIN GLP-1 RECEPTOR AGONIST MARKET SIZE, BY APPLICATION, 2025-2030 (USD MILLION)
TABLE 179. SPAIN GLP-1 RECEPTOR AGONIST MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2024 (USD MILLION)
TABLE 180. SPAIN GLP-1 RECEPTOR AGONIST MARKET SIZE, BY DISTRIBUTION CHANNEL, 2025-2030 (USD MILLION)
TABLE 181. UNITED ARAB EMIRATES GLP-1 RECEPTOR AGONIST MARKET SIZE, BY DRUG CLASS, 2018-2024 (USD MILLION)
TABLE 182. UNITED ARAB EMIRATES GLP-1 RECEPTOR AGONIST MARKET SIZE, BY DRUG CLASS, 2025-2030 (USD MILLION)
TABLE 183. UNITED ARAB EMIRATES GLP-1 RECEPTOR AGONIST MARKET SIZE, BY DRUG TYPE, 2018-2024 (USD MILLION)
TABLE 184. UNITED ARAB EMIRATES GLP-1 RECEPTOR AGONIST MARKET SIZE, BY DRUG TYPE, 2025-2030 (USD MILLION)
TABLE 185. UNITED ARAB EMIRATES GLP-1 RECEPTOR AGONIST MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2024 (USD MILLION)
TABLE 186. UNITED ARAB EMIRATES GLP-1 RECEPTOR AGONIST MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2025-2030 (USD MILLION)
TABLE 187. UNITED ARAB EMIRATES GLP-1 RECEPTOR AGONIST MARKET SIZE, BY APPLICATION, 2018-2024 (USD MILLION)
TABLE 188. UNITED ARAB EMIRATES GLP-1 RECEPTOR AGONIST MARKET SIZE, BY APPLICATION, 2025-2030 (USD MILLION)
TABLE 189. UNITED ARAB EMIRATES GLP-1 RECEPTOR AGONIST MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2024 (USD MILLION)
TABLE 190. UNITED ARAB EMIRATES GLP-1 RECEPTOR AGONIST MARKET SIZE, BY DISTRIBUTION CHANNEL, 2025-2030 (USD MILLION)
TABLE 191. SAUDI ARABIA GLP-1 RECEPTOR AGONIST MARKET SIZE, BY DRUG CLASS, 2018-2024 (USD MILLION)
TABLE 192. SAUDI ARABIA GLP-1 RECEPTOR AGONIST MARKET SIZE, BY DRUG CLASS, 2025-2030 (USD MILLION)
TABLE 193. SAUDI ARABIA GLP-1 RECEPTOR AGONIST MARKET SIZE, BY DRUG TYPE, 2018-2024 (USD MILLION)
TABLE 194. SAUDI ARABIA GLP-1 RECEPTOR AGONIST MARKET SIZE, BY DRUG TYPE, 2025-2030 (USD MILLION)
TABLE 195. SAUDI ARABIA GLP-1 RECEPTOR AGONIST MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2024 (USD MILLION)
TABLE 196. SAUDI ARABIA GLP-1 RECEPTOR AGONIST MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2025-2030 (USD MILLION)
TABLE 197. SAUDI ARABIA GLP-1 RECEPTOR AGONIST MARKET SIZE, BY APPLICATION, 2018-2024 (USD MILLION)
TABLE 198. SAUDI ARABIA GLP-1 RECEPTOR AGONIST MARKET SIZE, BY APPLICATION, 2025-2030 (USD MILLION)
TABLE 199. SAUDI ARABIA GLP-1 RECEPTOR AGONIST MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2024 (USD MILLION)
TABLE 200. SAUDI ARABIA GLP-1 RECEPTOR AGONIST MARKET SIZE, BY DISTRIBUTION CHANNEL, 2025-2030 (USD MILLION)
TABLE 201. SOUTH AFRICA GLP-1 RECEPTOR AGONIST MARKET SIZE, BY DRUG CLASS, 2018-2024 (USD MILLION)
TABLE 202. SOUTH AFRICA GLP-1 RECEPTOR AGONIST MARKET SIZE, BY DRUG CLASS, 2025-2030 (USD MILLION)
TABLE 203. SOUTH AFRICA GLP-1 RECEPTOR AGONIST MARKET SIZE, BY DRUG TYPE, 2018-2024 (USD MILLION)
TABLE 204. SOUTH AFRICA GLP-1 RECEPTOR AGONIST MARKET SIZE, BY DRUG TYPE, 2025-2030 (USD MILLION)
TABLE 205. SOUTH AFRICA GLP-1 RECEPTOR AGONIST MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2024 (USD MILLION)
TABLE 206. SOUTH AFRICA GLP-1 RECEPTOR AGONIST MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2025-2030 (USD MILLION)
TABLE 207. SOUTH AFRICA GLP-1 RECEPTOR AGONIST MARKET SIZE, BY APPLICATION, 2018-2024 (USD MILLION)
TABLE 208. SOUTH AFRICA GLP-1 RECEPTOR AGONIST MARKET SIZE, BY APPLICATION, 2025-2030 (USD MILLION)
TABLE 209. SOUTH AFRICA GLP-1 RECEPTOR AGONIST MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2024 (USD MILLION)
TABLE 210. SOUTH AFRICA GLP-1 RECEPTOR AGONIST MARKET SIZE, BY DISTRIBUTION CHANNEL, 2025-2030 (USD MILLION)
TABLE 211. DENMARK GLP-1 RECEPTOR AGONIST MARKET SIZE, BY DRUG CLASS, 2018-2024 (USD MILLION)
TABLE 212. DENMARK GLP-1 RECEPTOR AGONIST MARKET SIZE, BY DRUG CLASS, 2025-2030 (USD MILLION)
TABLE 213. DENMARK GLP-1 RECEPTOR AGONIST MARKET SIZE, BY DRUG TYPE, 2018-2024 (USD MILLION)
TABLE 214. DENMARK GLP-1 RECEPTOR AGONIST MARKET SIZE, BY DRUG TYPE, 2025-2030 (USD MILLION)
TABLE 215. DENMARK GLP-1 RECEPTOR AGONIST MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2024 (USD MILLION)
TABLE 216. DENMARK GLP-1 RECEPTOR AGONIST MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2025-2030 (USD MILLION)
TABLE 217. DENMARK GLP-1 RECEPTOR AGONIST MARKET SIZE, BY APPLICATION, 2018-2024 (USD MILLION)
TABLE 218. DENMARK GLP-1 RECEPTOR AGONIST MARKET SIZE, BY APPLICATION, 2025-2030 (USD MILLION)
TABLE 219. DENMARK GLP-1 RECEPTOR AGONIST MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2024 (USD MILLION)
TABLE 220. DENMARK GLP-1 RECEPTOR AGONIST MARKET SIZE, BY DISTRIBUTION CHANNEL, 2025-2030 (USD MILLION)
TABLE 221. NETHERLANDS GLP-1 RECEPTOR AGONIST MARKET SIZE, BY DRUG CLASS, 2018-2024 (USD MILLION)
TABLE 222. NETHERLANDS GLP-1 RECEPTOR AGONIST MARKET SIZE, BY DRUG CLASS, 2025-2030 (USD MILLION)
TABLE 223. NETHERLANDS GLP-1 RECEPTOR AGONIST MARKET SIZE, BY DRUG TYPE, 2018-2024 (USD MILLION)
TABLE 224. NETHERLANDS GLP-1 RECEPTOR AGONIST MARKET SIZE, BY DRUG TYPE, 2025-2030 (USD MILLION)
TABLE 225. NETHERLANDS GLP-1 RECEPTOR AGONIST MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2024 (USD MILLION)
TABLE 226. NETHERLANDS GLP-1 RECEPTOR AGONIST MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2025-2030 (USD MILLION)
TABLE 227. NETHERLANDS GLP-1 RECEPTOR AGONIST MARKET SIZE, BY APPLICATION, 2018-2024 (USD MILLION)
TABLE 228. NETHERLANDS GLP-1 RECEPTOR AGONIST MARKET SIZE, BY APPLICATION, 2025-2030 (USD MILLION)
TABLE 229. NETHERLANDS GLP-1 RECEPTOR AGONIST MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2024 (USD MILLION)
TABLE 230. NETHERLANDS GLP-1 RECEPTOR AGONIST MARKET SIZE, BY DISTRIBUTION CHANNEL, 2025-2030 (USD MILLION)
TABLE 231. QATAR GLP-1 RECEPTOR AGONIST MARKET SIZE, BY DRUG CLASS, 2018-2024 (USD MILLION)
TABLE 232. QATAR GLP-1 RECEPTOR AGONIST MARKET SIZE, BY DRUG CLASS, 2025-2030 (USD MILLION)
TABLE 233. QATAR GLP-1 RECEPTOR AGONIST MARKET SIZE, BY DRUG TYPE, 2018-2024 (USD MILLION)
TABLE 234. QATAR GLP-1 RECEPTOR AGONIST MARKET SIZE, BY DRUG TYPE, 2025-2030 (USD MILLION)
TABLE 235. QATAR GLP-1 RECEPTOR AGONIST MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2024 (USD MILLION)
TABLE 236. QATAR GLP-1 RECEPTOR AGONIST MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2025-2030 (USD MILLION)
TABLE 237. QATAR GLP-1 RECEPTOR AGONIST MARKET SIZE, BY APPLICATION, 2018-2024 (USD MILLION)
TABLE 238. QATAR GLP-1 RECEPTOR AGONIST MARKET SIZE, BY APPLICATION, 2025-2030 (USD MILLION)
TABLE 239. QATAR GLP-1 RECEPTOR AGONIST MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2024 (USD MILLION)
TABLE 240. QATAR GLP-1 RECEPTOR AGONIST MARKET SIZE, BY DISTRIBUTION CHANNEL, 2025-2030 (USD MILLION)
TABLE 241. FINLAND GLP-1 RECEPTOR AGONIST MARKET SIZE, BY DRUG CLASS, 2018-2024 (USD MILLION)
TABLE 242. FINLAND GLP-1 RECEPTOR AGONIST MARKET SIZE, BY DRUG CLASS, 2025-2030 (USD MILLION)
TABLE 243. FINLAND GLP-1 RECEPTOR AGONIST MARKET SIZE, BY DRUG TYPE, 2018-2024 (USD MILLION)
TABLE 244. FINLAND GLP-1 RECEPTOR AGONIST MARKET SIZE, BY DRUG TYPE, 2025-2030 (USD MILLION)
TABLE 245. FINLAND GLP-1 RECEPTOR AGONIST MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2024 (USD MILLION)
TABLE 246. FINLAND GLP-1 RECEPTOR AGONIST MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2025-2030 (USD MILLION)
TABLE 247. FINLAND GLP-1 RECEPTOR AGONIST MARKET SIZE, BY APPLICATION, 2018-2024 (USD MILLION)
TABLE 248. FINLAND GLP-1 RECEPTOR AGONIST MARKET SIZE, BY APPLICATION, 2025-2030 (USD MILLION)
TABLE 249. FINLAND GLP-1 RECEPTOR AGONIST MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2024 (USD MILLION)
TABLE 250. FINLAND GLP-1 RECEPTOR AGONIST MARKET SIZE, BY DISTRIBUTION CHANNEL, 2025-2030 (USD MILLION)
TABLE 251. SWEDEN GLP-1 RECEPTOR AGONIST MARKET SIZE, BY DRUG CLASS, 2018-2024 (USD MILLION)
TABLE 252. SWEDEN GLP-1 RECEPTOR AGONIST MARKET SIZE, BY DRUG CLASS, 2025-2030 (USD MILLION)
TABLE 253. SWEDEN GLP-1 RECEPTOR AGONIST MARKET SIZE, BY DRUG TYPE, 2018-2024 (USD MILLION)
TABLE 254. SWEDEN GLP-1 RECEPTOR AGONIST MARKET SIZE, BY DRUG TYPE, 2025-2030 (USD MILLION)
TABLE 255. SWEDEN GLP-1 RECEPTOR AGONIST MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2024 (USD MILLION)
TABLE 256. SWEDEN GLP-1 RECEPTOR AGONIST MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2025-2030 (USD MILLION)
TABLE 257. SWEDEN GLP-1 RECEPTOR AGONIST MARKET SIZE, BY APPLICATION, 2018-2024 (USD MILLION)
TABLE 258. SWEDEN GLP-1 RECEPTOR AGONIST MARKET SIZE, BY APPLICATION, 2025-2030 (USD MILLION)
TABLE 259. SWEDEN GLP-1 RECEPTOR AGONIST MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2024 (USD MILLION)
TABLE 260. SWEDEN GLP-1 RECEPTOR AGONIST MARKET SIZE, BY DISTRIBUTION CHANNEL, 2025-2030 (USD MILLION)
TABLE 261. NIGERIA GLP-1 RECEPTOR AGONIST MARKET SIZE, BY DRUG CLASS, 2018-2024 (USD MILLION)
TABLE 262. NIGERIA GLP-1 RECEPTOR AGONIST MARKET SIZE, BY DRUG CLASS, 2025-2030 (USD MILLION)
TABLE 263. NIGERIA GLP-1 RECEPTOR AGONIST MARKET SIZE, BY DRUG TYPE, 2018-2024 (USD MILLION)
TABLE 264. NIGERIA GLP-1 RECEPTOR AGONIST MARKET SIZE, BY DRUG TYPE, 2025-2030 (USD MILLION)
TABLE 265. NIGERIA GLP-1 RECEPTOR AGONIST MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2024 (USD MILLION)
TABLE 266. NIGERIA GLP-1 RECEPTOR AGONIST MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2025-2030 (USD MILLION)
TABLE 267. NIGERIA GLP-1 RECEPTOR AGONIST MARKET SIZE, BY APPLICATION, 2018-2024 (USD MILLION)
TABLE 268. NIGERIA GLP-1 RECEPTOR AGONIST MARKET SIZE, BY APPLICATION, 2025-2030 (USD MILLION)
TABLE 269. NIGERIA GLP-1 RECEPTOR AGONIST MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2024 (USD MILLION)
TABLE 270. NIGERIA GLP-1 RECEPTOR AGONIST MARKET SIZE, BY DISTRIBUTION CHANNEL, 2025-2030 (USD MILLION)
TABLE 271. EGYPT GLP-1 RECEPTOR AGONIST MARKET SIZE, BY DRUG CLASS, 2018-2024 (USD MILLION)
TABLE 272. EGYPT GLP-1 RECEPTOR AGONIST MARKET SIZE, BY DRUG CLASS, 2025-2030 (USD MILLION)
TABLE 273. EGYPT GLP-1 RECEPTOR AGONIST MARKET SIZE, BY DRUG TYPE, 2018-2024 (USD MILLION)
TABLE 274. EGYPT GLP-1 RECEPTOR AGONIST MARKET SIZE, BY DRUG TYPE, 2025-2030 (USD MILLION)
TABLE 275. EGYPT GLP-1 RECEPTOR AGONIST MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2024 (USD MILLION)
TABLE 276. EGYPT GLP-1 RECEPTOR AGONIST MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2025-2030 (USD MILLION)
TABLE 277. EGYPT GLP-1 RECEPTOR AGONIST MARKET SIZE, BY APPLICATION, 2018-2024 (USD MILLION)
TABLE 278. EGYPT GLP-1 RECEPTOR AGONIST MARKET SIZE, BY APPLICATION, 2025-2030 (USD MILLION)
TABLE 279. EGYPT GLP-1 RECEPTOR AGONIST MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2024 (USD MILLION)
TABLE 280. EGYPT GLP-1 RECEPTOR AGONIST MARKET SIZE, BY DISTRIBUTION CHANNEL, 2025-2030 (USD MILLION)
TABLE 281. TURKEY GLP-1 RECEPTOR AGONIST MARKET SIZE, BY DRUG CLASS, 2018-2024 (USD MILLION)
TABLE 282. TURKEY GLP-1 RECEPTOR AGONIST MARKET SIZE, BY DRUG CLASS, 2025-2030 (USD MILLION)
TABLE 283. TURKEY GLP-1 RECEPTOR AGONIST MARKET SIZE, BY DRUG TYPE, 2018-2024 (USD MILLION)
TABLE 284. TURKEY GLP-1 RECEPTOR AGONIST MARKET SIZE, BY DRUG TYPE, 2025-2030 (USD MILLION)
TABLE 285. TURKEY GLP-1 RECEPTOR AGONIST MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2024 (USD MILLION)
TABLE 286. TURKEY GLP-1 RECEPTOR AGONIST MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2025-2030 (USD MILLION)
TABLE 287. TURKEY GLP-1 RECEPTOR AGONIST MARKET SIZE, BY APPLICATION, 2018-2024 (USD MILLION)
TABLE 288. TURKEY GLP-1 RECEPTOR AGONIST MARKET SIZE, BY APPLICATION, 2025-2030 (USD MILLION)
TABLE 289. TURKEY GLP-1 RECEPTOR AGONIST MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2024 (USD MILLION)
TABLE 290. TURKEY GLP-1 RECEPTOR AGONIST MARKET SIZE, BY DISTRIBUTION CHANNEL, 2025-2030 (USD MILLION)
TABLE 291. ISRAEL GLP-1 RECEPTOR AGONIST MARKET SIZE, BY DRUG CLASS, 2018-2024 (USD MILLION)
TABLE 292. ISRAEL GLP-1 RECEPTOR AGONIST MARKET SIZE, BY DRUG CLASS, 2025-2030 (USD MILLION)
TABLE 293. ISRAEL GLP-1 RECEPTOR AGONIST MARKET SIZE, BY DRUG TYPE, 2018-2024 (USD MILLION)
TABLE 294. ISRAEL GLP-1 RECEPTOR AGONIST MARKET SIZE, BY DRUG TYPE, 2025-2030 (USD MILLION)
TABLE 295. ISRAEL GLP-1 RECEPTOR AGONIST MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2024 (USD MILLION)
TABLE 296. ISRAEL GLP-1 RECEPTOR AGONIST MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2025-2030 (USD MILLION)
TABLE 297. ISRAEL GLP-1 RECEPTOR AGONIST MARKET SIZE, BY APPLICATION, 2018-2024 (USD MILLION)
TABLE 298. ISRAEL GLP-1 RECEPTOR AGONIST MARKET SIZE, BY APPLICATION, 2025-2030 (USD MILLION)
TABLE 299. ISRAEL GLP-1 RECEPTOR AGONIST MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2024 (USD MILLION)
TABLE 300. ISRAEL GLP-1 RECEPTOR AGONIST MARKET SIZE, BY DISTRIBUTION CHANNEL, 2025-2030 (USD MILLION)
TABLE 301. NORWAY GLP-1 RECEPTOR AGONIST MARKET SIZE, BY DRUG CLASS, 2018-2024 (USD MILLION)
TABLE 302. NORWAY GLP-1 RECEPTOR AGONIST MARKET SIZE, BY DRUG CLASS, 2025-2030 (USD MILLION)
TABLE 303. NORWAY GLP-1 RECEPTOR AGONIST MARKET SIZE, BY DRUG TYPE, 2018-2024 (USD MILLION)
TABLE 304. NORWAY GLP-1 RECEPTOR AGONIST MARKET SIZE, BY DRUG TYPE, 2025-2030 (USD MILLION)
TABLE 305. NORWAY GLP-1 RECEPTOR AGONIST MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2024 (USD MILLION)
TABLE 306. NORWAY GLP-1 RECEPTOR AGONIST MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2025-2030 (USD MILLION)
TABLE 307. NORWAY GLP-1 RECEPTOR AGONIST MARKET SIZE, BY APPLICATION, 2018-2024 (USD MILLION)
TABLE 308. NORWAY GLP-1 RECEPTOR AGONIST MARKET SIZE, BY APPLICATION, 2025-2030 (USD MILLION)
TABLE 309. NORWAY GLP-1 RECEPTOR AGONIST MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2024 (USD MILLION)
TABLE 310. NORWAY GLP-1 RECEPTOR AGONIST MARKET SIZE, BY DISTRIBUTION CHANNEL, 2025-2030 (USD MILLION)
TABLE 311. POLAND GLP-1 RECEPTOR AGONIST MARKET SIZE, BY DRUG CLASS, 2018-2024 (USD MILLION)
TABLE 312. POLAND GLP-1 RECEPTOR AGONIST MARKET SIZE, BY DRUG CLASS, 2025-2030 (USD MILLION)
TABLE 313. POLAND GLP-1 RECEPTOR AGONIST MARKET SIZE, BY DRUG TYPE, 2018-2024 (USD MILLION)
TABLE 314. POLAND GLP-1 RECEPTOR AGONIST MARKET SIZE, BY DRUG TYPE, 2025-2030 (USD MILLION)
TABLE 315. POLAND GLP-1 RECEPTOR AGONIST MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2024 (USD MILLION)
TABLE 316. POLAND GLP-1 RECEPTOR AGONIST MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2025-2030 (USD MILLION)
TABLE 317. POLAND GLP-1 RECEPTOR AGONIST MARKET SIZE, BY APPLICATION, 2018-2024 (USD MILLION)
TABLE 318. POLAND GLP-1 RECEPTOR AGONIST MARKET SIZE, BY APPLICATION, 2025-2030 (USD MILLION)
TABLE 319. POLAND GLP-1 RECEPTOR AGONIST MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2024 (USD MILLION)
TABLE 320. POLAND GLP-1 RECEPTOR AGONIST MARKET SIZE, BY DISTRIBUTION CHANNEL, 2025-2030 (USD MILLION)
TABLE 321. SWITZERLAND GLP-1 RECEPTOR AGONIST MARKET SIZE, BY DRUG CLASS, 2018-2024 (USD MILLION)
TABLE 322. SWITZERLAND GLP-1 RECEPTOR AGONIST MARKET SIZE, BY DRUG CLASS, 2025-2030 (USD MILLION)
TABLE 323. SWITZERLAND GLP-1 RECEPTOR AGONIST MARKET SIZE, BY DRUG TYPE, 2018-2024 (USD MILLION)
TABLE 324. SWITZERLAND GLP-1 RECEPTOR AGONIST MARKET SIZE, BY DRUG TYPE, 2025-2030 (USD MILLION)
TABLE 325. SWITZERLAND GLP-1 RECEPTOR AGONIST MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2024 (USD MILLION)
TABLE 326. SWITZERLAND GLP-1 RECEPTOR AGONIST MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2025-2030 (USD MILLION)
TABLE 327. SWITZERLAND GLP-1 RECEPTOR AGONIST MARKET SIZE, BY APPLICATION, 2018-2024 (USD MILLION)
TABLE 328. SWITZERLAND GLP-1 R

Samples

Loading
LOADING...

Companies Mentioned

  • Eli Lilly and Company
  • Sanofi
  • Novo-Nordisk A/S
  • AstraZeneca
  • Pfizer.Inc
  • Amgen, Inc.
  • Innovent Biologics, Inc.
  • PegBio Co., Ltd.
  • Sun Pharmaceutical Industries Ltd.
  • Boehringer Ingelheim International GmbH

Table Information

Report AttributeDetails
No. of Pages186
PublishedAugust 2025
Forecast Period2025 - 2030
Estimated Market Value ( USD ) in 2025 $ 45.59 Billion
Forecasted Market Value ( USD ) by 2030 $ 85.55 Billion
Compound Annual Growth Rate13.3%
Regions CoveredGlobal
No. of Companies Mentioned10

Related Topics

Related Reports

GLP-1 Receptor Agonist Market Size, Share & Trends Analysis Report By Product (Ozempic, Zepbound), By Application (Diabetes, Obesity), By Route Of Administration (Parenteral, Oral), By Region, And Segment Forecasts, 2025 - 2030 - Product Image

GLP-1 Receptor Agonist Market Size, Share & Trends Analysis Report By Product (Ozempic, Zepbound), By Application (Diabetes, Obesity), By Route Of Administration (Parenteral, Oral), By Region, And Segment Forecasts, 2025 - 2030

  • Report
  • 150 Pages
  • Global
From
GLP-1 Receptor Agonist Market Report 2025 - Product Image

GLP-1 Receptor Agonist Market Report 2025

  • Report
  • 200 Pages
  • Global
From
GLP-1 Receptor Agonist Global Market Insights 2025, Analysis and Forecast to 2030, by Market Participants, Regions, Technology, Application, Product Type - Product Image

GLP-1 Receptor Agonist Global Market Insights 2025, Analysis and Forecast to 2030, by Market Participants, Regions, Technology, Application, Product Type

  • Report
  • 73 Pages
  • Global
From
GLP-1 Receptor Agonist - Global Strategic Business Report - Product Image

GLP-1 Receptor Agonist - Global Strategic Business Report

  • Report
  • 483 Pages
  • Global
From
India GLP-1 Receptor Agonist Market Size, Share & Trends Analysis Report By Application (Diabetes, Obesity), By Route of Administration (Parenteral, Oral), By Product, By Distribution Channel, And Segment Forecasts, 2025 - 2030 - Product Image

India GLP-1 Receptor Agonist Market Size, Share & Trends Analysis Report By Application (Diabetes, Obesity), By Route of Administration (Parenteral, Oral), By Product, By Distribution Channel, And Segment Forecasts, 2025 - 2030

  • Report
  • 150 Pages
  • India
From

About the GLP-1 Receptor Agonist Market

The GLP-1 Receptor Agonist market is a subset of the Central Nervous System Drugs market. GLP-1 Receptor Agonists are drugs that act on the GLP-1 receptor, a protein found in the brain and other parts of the body. These drugs are used to treat a variety of conditions, including obesity, type 2 diabetes, and depression. GLP-1 Receptor Agonists work by stimulating the release of insulin and other hormones, which can help regulate blood sugar levels and reduce appetite. GLP-1 Receptor Agonists are typically administered as injections, and are often used in combination with other medications. They are generally well-tolerated, with few side effects. However, they can be expensive, and may not be covered by insurance. Some companies in the GLP-1 Receptor Agonist market include Novo Nordisk, Eli Lilly, AstraZeneca, and Sanofi. Show Less Read more

Copyright © 2002-2025 Research and Markets. All Rights Reserved.